Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, Inc. (NRXS) on August 19, 2026, covering events occurring between July 24, 2026, and August 13, 2026. The Company is incorporated in Delaware and trades on the NYSE American. The filing primarily addresses executive and director compensation adjustments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation events rather than financial performance results.
Material Changes and Events
- Stock Option Exchange Effective Date: On July 24, 2026, a previously approved exchange of 1,319,394 outstanding stock options for an equivalent number of Restricted Stock Units (RSUs) became effective. This exchange was approved by stockholders on June 10, 2026.
- Executive RSU Grants: On August 13, 2026, the Compensation Committee granted new RSUs to key executives under the 2022 Omnibus Securities and Incentive Plan. These awards vest in three equal annual installments over three years.
- Director Equity Awards: On August 13, 2026, the Company granted a total of 127,120 shares of common stock to independent directors as a one-time award to address historical compensation levels below market rates.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors. Management commentary is limited to the rationale for the director equity awards, citing an independent compensation consultant's review which determined that historical compensation was below applicable market levels.
Investor Verification Checklist
- Verify the total number of RSUs granted to executives (Brian Carrico: 193,329; Timothy Henrichs: 141,479; Adrian Miranda: 133,341; Thomas Carrico: 135,906) and their vesting schedules.
- Confirm the immediate vesting status of the 591,972 RSUs received by executives (Brian Carrico: 199,188; Adrian Miranda: 199,106; Thomas Carrico: 193,678) via the Stock Option Exchange.
- Review the impact of the 127,120 shares granted to independent directors on total share count and potential dilution.
- Check subsequent filings for the financial impact of these equity awards on the Company's compensation expense.